Why carry out this study?

Migraine attacks have a notable impact on people’s daily lives, health-related quality of life (HRQoL), and ability to work.

HRQoL and work productivity are likely to pose particular problems for patients whose migraine attacks do not respond sufficiently to commonly used acute treatments such as triptans.

This real-world study aimed to determine whether migraine-related HRQoL, disability, and work productivity differed between people reporting insufficient efficacy (triptan insufficient responders) and sufficient efficacy (triptan sufficient responders) with triptans as acute treatment for migraine in Japan.

What was learned from the study?

Migraine-related disability was higher, and migraine-related HRQoL and work productivity were significantly lower, in triptan insufficient responders (based on insufficient efficacy) than in triptan sufficient responders.

The negative impact of migraine attacks on the HRQoL, ability to perform in daily life, and work productivity of people in Japan reporting insufficient efficacy with acute triptan treatment highlights the need for additional effective acute treatment options.